LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures
8.2.2023 17:00:00 EET | Business Wire | Press release
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has been initiated in select centers throughout Europe, following a successful clinical experience in two major centers, Catharina Hospital in Eindhoven, Netherlands and San Donato Hospital in Milan, Italy. Consisting of a next-generation heart-lung machine (HLM) and a transformative patient monitor, Essenz puts data at the forefront to deliver a patient-tailored approach that supports data-driven decisions during life-saving cardiopulmonary bypass (CPB) procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005127/en/
LivaNova's Essenz™ Perfusion System (Photo: Business Wire)
Catharina Hospital was the first hospital in the world to carry out clinical cases with the Essenz Perfusion System. “We are proud to be the first to have introduced the Essenz Perfusion System to our clinical practice, particularly given the great involvement we had with the system throughout the development process,” said Eddy Overdevest, Perfusionist at Catharina Hospital. “From the first day in the operating room, we felt a level of confidence that has allowed us to immediately move into a variety of clinical cases, trusting the system and our own ability to work with it. With the Essenz Perfusion System, we’re entering a new era where technology and the expertise of the perfusionist can seamlessly come together to provide personalized care for our patients.”
“We are very satisfied with the way the machine is performing and excited to finally be able to use it to support patients during open-heart procedures,” said Mauro Cotza, Chief Perfusionist at San Donato Hospital. “We were pleased to be the first hospital in the world to place a patient on bypass with Essenz during a minimally invasive mitral valve replacement surgery.”
The Essenz Perfusion System is based on 50 years of trusted partnership with perfusionists. LivaNova worked hand in hand with more than 300 perfusionists around the world who participated during every step of design and development to address their evolving needs in the operating room (OR), with an emphasis on patient safety and risk management. The comprehensive system provides flexibility and scalability to optimize intra-operative care coordination.
The Essenz Perfusion System is built on the legacy LivaNova S5™ HLM. The Essenz HLM cockpit and Essenz Patient Monitor are connected but operate separately. Plus, each pump on Essenz is controlled individually.
Accurate sensing technology and an intuitive dashboard on the Essenz Patient Monitor provide data during a case. With an intuitive user interface, the Essenz Patient Monitor continuously records and displays data and events together to assist the perfusionist throughout a procedure.
The Essenz Perfusion System features an ergonomic design, including advanced cable management and a mast-mounted design to keep the area clean and hygienic. The innovative cockpit provides one central view to control the device and check all perfusion and patient parameters. Mast-mounted pumps allow the user to position the disposables at their discretion (i.e., oxygenator and perfusion tubing set).
Further, the Essenz Perfusion System is backed by a responsive service team of dedicated, local engineers in more than 100 countries, along with a global support center to address any needs.
“During open-heart procedures, perfusionists play a critical role and the perfusion system they use acts as the patient’s heart and lungs during the operation,” said Marco Dolci, President, Cardiopulmonary at LivaNova. “Throughout the Essenz design process, we heard directly from perfusionists that they need a flexible and reliable system that gives them access to comprehensive data to inform their patient-tailored support in the OR. With the combination of next-generation hardware and software, the Essenz Perfusion System will serve patients and empower perfusionists to make informed decisions as they provide increasingly tailored patient care.”
Both the Essenz HLM and Essenz Patient Monitor have received CE Mark and are currently pending regulatory approval in other key geographies. Learn more about the Essenz Perfusion System and Essenz Patient Monitor on the LivaNova website.
*Note: The Essenz Heart-Lung Machine is not available for sale in all geographies. Visit the LivaNova website for important safety information. Not available in Canada or the U.S. 510(k) clearance pending.
About LivaNova
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Essenz Perfusion System, Essenz HLM and the Essenz Patient Monitor. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005127/en/
Contact information
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Speech Processing Solutions Launches Philips SpeechLive Health, an AI Assistant Built for Modern Clinical Documentation17.3.2026 16:00:00 EET | Press release
Speech Processing Solutions, the global leader in professional dictation and speech solutions sold under the Philips brand, today announced the upcoming April 2026 launch of Philips SpeechLive Health AI Assistant, an AI-powered clinical documentation assistant designed for healthcare professionals across multiple care settings. This solution reduces administrative burden, streamlines documentation, and improves provider and patient experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317743584/en/ Philips SpeechLive Health AI Assistant turns clinical conversations into structured documentation, helping reduce administrative workload and create more time for patient care. Purpose-built for clinical documentation workflows Clinical workload remains a major challenge across healthcare. In the U.S., AMIA’s 2024 TrendBurden survey found that 77% of healthcare professionals said documentation makes them work late or at h
Coherent Solutions Releases Research on AI-driven Fraud Prevention in Banking and Finance and the Best AI Models for Banks17.3.2026 16:00:00 EET | Press release
Coherent Solutions has released a Future of Finance research illustrating how AI is advancing fraud detection in financial services. The research offers financial institutions a strategic framework to address rising and more sophisticated fraud techniques with adaptive, human-in-the-loop AI systems, based on the firm’s extensive experience in AI engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317526196/en/ Coherent Solutions releases research on AI-driven fraud prevention. This white paper addresses the modern threat of transaction fraud, which is becoming faster and smarter while conventional rule-based systems lag, leaving financial institutions exposed. Banks, credit lenders, and financial institutions that adopt AI and machine learning can reduce fraud losses by up to 50% and detect anomalies in real time. When implemented with proper governance and human oversight, AI systems also make audits smoother and
The Swoosh Meets the ‘b’: Beats and Nike Unveil Historic First-Ever Collaboration for Powerbeats Pro 217.3.2026 16:00:00 EET | Press release
Today, Beats and Nike announced the first hardware collaboration in their shared history: Powerbeats Pro 2 – Nike Special Edition. In a landmark design shift, Beats has—for the first time—shared its iconic earbud real estate with a partner, featuring the Nike Swoosh on the right bud and the signature Beats “b” on the left. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317159868/en/ Powerbeats Pro 2 - Nike Special Edition The limited-edition release marries Nike’s high-energy “Volt” color palette with the industry-leading audio tech of the Powerbeats Pro 2. The result is a performance tool built to bridge the gap between elite sport and street style. The Nike Special Edition arrives in a striking matte black, Volt-speckled charging case. Upon opening, users are greeted by Nike’s “JUST DO IT” mantra printed inside the lid. While the aesthetic is new, the internals are pure power: Pro-Level Sound: Adaptive Active Noise Canc
Moody’s Ratings Becomes First Credit Rating Agency to Bring Independent Credit Analysis to Blockchain Financial Infrastructure17.3.2026 16:00:00 EET | Press release
Moody’s Corporation (NYSE: MCO) today announced that Moody’s Ratings has launched its network-agnostic Token Integration Engine™ (TIE), becoming the first credit rating agency to ingest analytical data and share credit insights on-chain. As an inaugural step, it is the first rating agency to operate a node on the Canton Network. The milestone marks a significant step in Moody’s commitment to digital innovation, intending to enable secure, compliant, and efficient ingestion of data and dissemination of ratings enabled by technology built for integration across platforms. “As financial markets digitize, the need for independent, trusted risk analysis and credit insights does not change,” said Fabian Astic, Managing Director and Global Head of Digital Economy at Moody’s Ratings. “Moody’s Ratings is extending that rigor to digital market infrastructure consistent with global regulatory expectations and our governance, transparency, and compliance practices.” Moody’s Ratings’ TIE serves as
Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care17.3.2026 15:46:00 EET | Press release
Sub‑Q Bionics, a medical device company developing an innovative implantable lymphatic drainage system designed to help patients living with lymphedema better manage their symptoms, today announced a licensing agreement with Mayo Clinic. Through the agreement, Sub-Q Bionics has licensed clinical know-how from Mayo Clinic related to reconstructive and lymphatic surgery. As part of this collaboration, Vahe Fahradyan, M.D., a plastic and reconstructive surgeon with expertise in lymphatic surgery, plans to work with Sub-Q Bionics as a clinical collaborator supporting the company’s ongoing development activities. Lymphedema is a chronic condition caused by impaired lymphatic drainage that can lead to persistent swelling, discomfort, and reduced mobility. It commonly occurs following cancer treatment, particularly among breast cancer survivors. Sub-Q Bionics is developing the world’s first implantable bionic lymphatic drainage system designed to assist with movement of lymphatic fluid and he
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom